Collective Strategies to Enhance Proportionate Enrollment

Topics Included: Access to Clinical Trials, Patient Engagement, Recruitment, Regulatory Submissions + Approvals, Site Planning

The Collective Strategies to Enhance Proportionate Enrollment project focuses on improving accountability, clarity, and communication across clinical trials partner groups to support more effective recruitment, enrollment, and retention practices. This effort seeks to understand and address the challenges, expectations, and needs of each group involved in clinical trials, including contract research organizations, patient organizations, sites, and sponsors.

By fostering action-focused and unified engagement throughout the clinical trials process, the project aims to identify practical solutions that help plan, design, and execute trials better positioned to recruit and retain participants who reflect the epidemiology and scientific evidence of the disease under study. These efforts will support the generation of reliable, relevant, and robust data to inform the development of safe and effective medical products for all populations.

Key Takeaways

Resources

Access to Clinical Trials | CTTI News

New CTTI Project Aims to Identify Challenges and Solutions to Strengthen Proportionate Enrollment in Clinical Trials

In December 2024, CTTI launched the Collective Strategies to Enhance Proportionate Enrollment project to improve communication, accountability and clarity across clinical trial partner groups.

Patient Engagement | Expert Meetings

Increasing Diversity in Clinical Trials Expert Meeting

OCTOBER 12 & 21, 2021 CTTI Project: Diversity Meeting Objectives: Present findings from project evidence generation: in-depth interviews with key decision-makers. Refine a maturity model for organizational-level strategies to increase...

Patient Engagement | Webinars

Increasing Diversity in Clinical Trials Recommendations Launch

CTTI Project: Increasing Diversity in Clinical Trials (more…)

Access to Clinical Trials | CTTI News

New Publication by CTTI, DCRI, the Duke Margolis Institute for Health Policy, and Protas Investigates Practices to Improve Evidence Generation System in Clinical Trials

A new publication developed in collaboration by CTTI, the Duke Clinical Research Institute (DCRI), the Duke Margolis Institute for Health Policy, and Protas published in Trials highlights the current barriers...

Patient Engagement | Resources

Enhancing Clinical Study Diversity Workshop Report

Enhancing Clinical Study Diversity Workshop Report

Access to Clinical Trials | CTTI News

Report Now Available: Virtual Public Workshop to Enhance Clinical Study Diversity

The report of the two-day virtual public workshop to enhance clinical study diversity, convened by the U.S. Food and Drug Administration (FDA) in collaboration with the Clinical Trials Transformation Initiative...

Patient Engagement | Resources

Toward a National Action Plan for Achieving Diversity in Clinical Trials

Toward a National Action Plan for Achieving Diversity in Clinical Trials

Patient Engagement | Media Coverage

How to Measure Progress in Improving Clinical Trial Diversity

The last several years have included many actions and acknowledgments of the need to improve the equitable access to and diverse participation in clinical trials.

Access to Clinical Trials | CTTI News

Recording Now Available: CTTI Webinar Unveiling New Recommendations on Increasing Diversity in Clinical Trials

A recording of CTTI’s May 18 webinar unveiling the new recommendations on increasing diversity in clinical trials is now available. The one-hour webinar includes a welcome from Sally Okun, CTTI;...

Formats

Stage of Trial

New CTTI Project Aims to Identify Challenges and Solutions to Strengthen Proportionate Enrollment in Clinical Trials 

CTTI News | December 3, 2024

Topics Included: Access to Clinical Trials

In December 2024, CTTI launched the Collective Strategies to Enhance Proportionate Enrollment project to improve communication, accountability and clarity across clinical trial partner groups. The project focuses on addressing persistent challenges that hinder the enrollment and retention of participants who reflect the populations most affected by the disease under study. 

Through this effort, CTTI aims to foster unified, action-focused collaboration among sponsors, contract research organizations, sites, patient organizations and other key groups involved in clinical research. By strengthening coordination and aligning expectations, the project will help identify practical strategies to improve how trials are planned and executed. 

To inform this work, CTTI is gathering evidence through qualitative methods, including interviews with individuals involved in clinical trial operations, to better understand group-specific needs and challenges. These insights will shape a set of recommendations and tools that clarify roles, outline implementation considerations and support proportionate enrollment across the trial lifecycle. 

Ultimately, this project will support the generation of high-quality, reliable data and the development of medical products that are safe and effective for all populations. These efforts align with CTTI’s Transforming Trials 2030 vision to create a more efficient, patient-centered and representative clinical trial enterprise. 

Increasing Diversity in Clinical Trials Expert Meeting

OCTOBER 12 & 21, 2021

CTTI Project: Diversity

Meeting Objectives:

  • Present findings from project evidence generation: in-depth interviews with key decision-makers.
  • Refine a maturity model for organizational-level strategies to increase diversity in clinical trials.
  • Identify specific multi-stakeholder, portfolio-level strategies to increase the participation of underrepresented racial and ethnic minorities and women in clinical trials.

The views and opinions expressed in this presentation are those of the individual presenter and should not be attributed to the Clinical Trials Transformation Initiative, or any organization with which the presenter is employed or affiliated.

Increasing Diversity in Clinical Trials Recommendations Launch

CTTI Project: Increasing Diversity in Clinical Trials

Webinar Presenters:

  • Richardae Araojo, U.S. Food & Drug Administration (FDA)
  • Ruma Bhagat, Genentech - a member of the Roche Group
  • Sara Calvert, CTTI
  • Luther T. Clark, Merck & Co, LLC
  • Dawn Corbett, National Institutes of Health Office of Extramural Research (OER)
  • Tesheia Johnson, Yale University
  • Jane Williams, Syneos Health
  • Glendon Zinser, Susan G. Komen

Webinar Resources:

Download PowerPoint slideset

New Publication by CTTI, DCRI, the Duke Margolis Institute for Health Policy, and Protas Investigates Practices to Improve Evidence Generation System in Clinical Trials

CTTI News | September 17, 2024

Topics Included: Access to Clinical Trials

new publication developed in collaboration by CTTI, the Duke Clinical Research Institute (DCRI), the Duke Margolis Institute for Health Policy, and Protas published in Trials highlights the current barriers to clinical trial transformation, areas of improvement, and actions needed to transform clinical evidence generation in the United States to better align with clinical care demands. A modern clinical trial infrastructure should prioritize trial accessibility, answer relevant study questions reliably, respond to public health emergencies rapidly, and more. 

The article identifies three key barriers that are currently impeding the transformation of the clinical trial evidence generation system – gaps in policy, inefficient infrastructure, and a lack of research prioritization. The United States’ health and data system has a fragmented infrastructure that can hamper the progress of clinical trials, especially at locations not accustomed to participating in research. Taking advantage of tools that increase trial efficiency will help significantly improve trial activation and participation. Regulatory support and appropriate policies are needed to implement a modern clinical trial infrastructure.  

Lastly, clinical trials are often deprioritized in health care settings because incentives to participate in trials are often limited and/or misaligned with clinical care activities. Health system leadership should encourage integration of trials more routinely into care delivery and help advance a learning health care system, especially as systems implement reforms to improve their clinical data infrastructure. 

Reliable and better evidence can be generated if there is continued movement towards more simple trial designs, regulatory clarity, the creation of a sustainable systemwide infrastructure, and coordinated leadership to improve the research and health care culture. 

Report Now Available: Virtual Public Workshop to Enhance Clinical Study Diversity

The report of the two-day virtual public workshop to enhance clinical study diversity, convened by the U.S. Food and Drug Administration (FDA) in collaboration with the Clinical Trials Transformation Initiative (CTTI), is now available. The workshop was held on November 29 and 30, 2023 with more than 2,600 global attendees. 

The workshop solicited input on strategies and considerations for increasing the enrollment of historically underrepresented populations in clinical studies and encouraging clinical study participation that reflects the prevalence of diseases or conditions among demographic subgroups. Speakers and panelists included representatives from the FDA and other federal agencies, academia, medical device and pharmaceutical sponsors, patients and patient advocacy groups, and research study teams. 

The workshop fulfilled a requirement under section 3603 of the Food and Drug Omnibus Reform Act of 2022 (FDORA). View the recording and slide deck to learn more. 

Recording Now Available: CTTI Webinar Unveiling New Recommendations on Increasing Diversity in Clinical Trials

A recording of CTTI’s May 18 webinar unveiling the new recommendations on increasing diversity in clinical trials is now available. 

The one-hour webinar includes a welcome from Sally Okun, CTTI; opening remarks from Richardae Araojo, U.S. Food and Drug Administration (FDA); a project overview from Luther Clark, Merck; a maturity model overview from Dawn Corbett, NIH; and a panel discussion moderated by Sara Calvert, CTTI. The panel discussion focused on stakeholder perspectives related to the integration of the of the new diversity recommendations and included Ruma Bhagat, Genentech-a member of the Roche Group; Tesheia Johnson, Yale; Jane Williams, Syneos Health; and Glendon Zinser, Susan G. Komen. 

The goal of creating these diversity recommendations is to increase the inclusion and adequate representation of women and historically underrepresented racial and ethnic groups in clinical trials to facilitate more accurate and generalizable trial results by enhancing and expanding our understanding of the safety and efficacy of investigational medical products. These recommendations were developed in collaboration with experts and key stakeholders from across the clinical trials enterprise using CTTI’s five-step methodology designed to ensure they are actionable, evidence-based, and consensus-driven. The first phase involved gathering input through qualitative, in-depth interviews with senior-level leaders at organizations conducting clinical trials to gather perspectives on strategies to support diversity and inclusion in clinical research. The recommendations were drafted and refined with input from a multi-stakeholder project team and through a 2-day Expert Meeting. 

View the slide deck to read more.